Literature DB >> 7539888

Amino acids of the human growth hormone receptor that are required for proliferation and Jak-STAT signaling.

Y D Wang1, W I Wood.   

Abstract

Dimerization of the GH receptor after ligand binding leads to the rapid association and tyrosine phosphorylation of the intracellular kinase, Jak2, as well as to the tyrosine phosphorylation and activation of STAT protein(s). The tyrosine phosphorylation of these and other related proteins has been shown to be required for intracellular signaling by the interferon receptors. Carboxyl-terminal truncations of the human GH receptor have been used to demonstrate that a 54-amino acid, intracellular region of the receptor is sufficient to signal cell proliferation in response to ligand binding. In this work, we examine 10 single and double amino acid mutations of this 54-amino acid region for their ability to signal the proliferation of stably transfected Ba/F3 cells, an interleukin-3 dependent pro-B cell line. The mutation of either of two proline residues or of a lysine residue abolished the GH-induced proliferation. These amino acids are located in or adjacent to a proline-rich sequence known as box 1 that is weakly conserved in other receptors of the GH/cytokine receptor family. The tyrosine phosphorylation of Jak2, as well as the activation of transcription factors (as judged by electrophoretic mobility shift assays), was also induced by GH in the transfected Ba/F3 cells. A consistent pattern of proliferation, Jak2 phosphorylation, and transcription factor activation was found for the 10 GH receptor mutants, a finding that is consistent with the hypothesis that the Jak-STAT pathway is required for the signaling of proliferation in these cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539888     DOI: 10.1210/mend.9.3.7539888

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  7 in total

1.  A novel and functional interaction between cyclophilin A and prolactin receptor.

Authors:  Farhat Syed; Michael A Rycyzyn; Liz Westgate; Charles V Clevenger
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

Review 2.  The prolactin/growth hormone receptor family: structure/function relationships.

Authors:  V Goffin; P A Kelly
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

Review 3.  Mice with gene alterations in the GH and IGF family.

Authors:  Yanrong Qian; Darlene E Berryman; Reetobrata Basu; Edward O List; Shigeru Okada; Jonathan A Young; Elizabeth A Jensen; Stephen R C Bell; Prateek Kulkarni; Silvana Duran-Ortiz; Patricia Mora-Criollo; Samuel C Mathes; Alison L Brittain; Mat Buchman; Emily Davis; Kevin R Funk; Jolie Bogart; Diego Ibarra; Isaac Mendez-Gibson; Julie Slyby; Joseph Terry; John J Kopchick
Journal:  Pituitary       Date:  2021-11-19       Impact factor: 4.107

Review 4.  Breast Cancer and Prolactin - New Mechanisms and Models.

Authors:  Charles V Clevenger; Hallgeir Rui
Journal:  Endocrinology       Date:  2022-10-01       Impact factor: 5.051

5.  Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy.

Authors:  K D O'Neal; M V Chari; C H Mcdonald; R G Cook; L Y Yu-Lee; J D Morrisett; W T Shearer
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

6.  Human Milk Cells Contain Numerous miRNAs that May Change with Milk Removal and Regulate Multiple Physiological Processes.

Authors:  Mohammed Alsaweed; Ching Tat Lai; Peter E Hartmann; Donna T Geddes; Foteini Kakulas
Journal:  Int J Mol Sci       Date:  2016-06-17       Impact factor: 5.923

7.  Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein.

Authors:  Ankur Rughani; Dongsheng Zhang; Kanimozhi Vairamani; Andrew Dauber; Vivian Hwa; Sowmya Krishnan
Journal:  Clin Endocrinol (Oxf)       Date:  2020-01-22       Impact factor: 3.478

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.